Gut Microbiome Modulates Efficacy of Immune Checkpoint Inhibitors

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2018 Mar 28

PMID 29580257

Citations 100

Authors

Ming Yi

Shengnan Yu

Shuang Qin

Qian Liu

Hanxiao Xu

Weiheng Zhao

Qian Chu

Kongming Wu

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors (ICIs) therapy is a novel strategy for cancer treatments in recent years. However, it was observed that most patients treated with ICIs could not get benefit from the therapy, which led to the limitation of clinical application. Motivated by potent and durable efficacy of ICIs, oncologists endeavor to explore the mechanisms of resistance to ICIs and increase the drug sensitivity. It is known that heterogeneity of gut microbiome in populations may result in different outcomes of therapy. In xenograft model, bacteria in gut have been proved as a crucial factor regulating immunotherapy efficacy. And the similar phenomenon was obtained in patients. In this review, we summarized relevant advancements about gut microbiome and ICIs. Furthermore, we focused on modulatory function of gut microbiome in ICIs therapy and possible antitumor mechanism of specific commensals in ICIs treatment. We propose that gut microbiome is an important predictive factor, and manipulation of gut microbiome is feasible to elevate response rate in ICIs therapy.

Citing Articles

Polysaccharides from Sea Cucumber () Synergize with Anti-PD1 Immunotherapy to Reduce MC-38 Tumor Burden in Mice Through Shaping the Gut Microbiome.

Li J, Jia J, Teng Y, Wang X, Xia X, Song S Foods. 2025; 14(3).

PMID: 39941980 PMC: 11816646. DOI: 10.3390/foods14030387.

Gut microbiota and metabolites associated with immunotherapy efficacy in extensive-stage small cell lung cancer: a pilot study.

Sun L, Wang X, Zhou H, Li R, Meng M, Roviello G J Thorac Dis. 2024; 16(10):6936-6954.

PMID: 39552845 PMC: 11565349. DOI: 10.21037/jtd-24-1201.

Dietary pattern and the corresponding gut microbiome in response to immunotherapy in Thai patients with advanced non-small cell lung cancer (NSCLC).

Sitthideatphaiboon P, Somlaw N, Zungsontiporn N, Ouwongprayoon P, Sukswai N, Korphaisarn K Sci Rep. 2024; 14(1):27791.

PMID: 39537963 PMC: 11561170. DOI: 10.1038/s41598-024-79339-6.

MDM2 inhibitors in cancer immunotherapy: Current status and perspective.

Zeng Q, Zeng S, Dai X, Ding Y, Huang C, Ruan R Genes Dis. 2024; 11(6):101279.

PMID: 39263534 PMC: 11388719. DOI: 10.1016/j.gendis.2024.101279.

Revolutionizing Skin Cancer Treatment: The Rise of PD-1/PDL-1 and CTLA-4 as Key Therapeutic Targets.

Sharma N, Mazumder R, Rai P Curr Drug Targets. 2024; 25(15):1012-1026.

PMID: 39257156 DOI: 10.2174/0113894501320281240822052657.

References

Wen L, Ley R, Volchkov P, Stranges P, Avanesyan L, Stonebraker A . Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature. 2008; 455(7216):1109-13. PMC: 2574766. DOI: 10.1038/nature07336. View

Furusawa Y, Obata Y, Fukuda S, Endo T, Nakato G, Takahashi D . Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013; 504(7480):446-50. DOI: 10.1038/nature12721. View

Wang G, Kurra V, Gainor J, Sullivan R, Flaherty K, Lee S . Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings. Radiographics. 2017; 37(7):2132-2144. DOI: 10.1148/rg.2017170085. View

Vetizou M, Pitt J, Daillere R, Lepage P, Waldschmitt N, Flament C . Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015; 350(6264):1079-84. PMC: 4721659. DOI: 10.1126/science.aad1329. View

Ok C, Young K . Checkpoint inhibitors in hematological malignancies. J Hematol Oncol. 2017; 10(1):103. PMC: 5422942. DOI: 10.1186/s13045-017-0474-3. View

Roy S, Trinchieri G . Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017; 17(5):271-285. DOI: 10.1038/nrc.2017.13. View

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

Blacher E, Levy M, Tatirovsky E, Elinav E . Microbiome-Modulated Metabolites at the Interface of Host Immunity. J Immunol. 2017; 198(2):572-580. DOI: 10.4049/jimmunol.1601247. View

Vetizou M, Daillere R, Zitvogel L . [The role of intestinal microbiota in the response to anti-tumor therapies]. Med Sci (Paris). 2016; 32(11):974-982. DOI: 10.1051/medsci/20163211013. View

10.

Tai N, Wong F, Wen L . The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity. Rev Endocr Metab Disord. 2015; 16(1):55-65. PMC: 4348024. DOI: 10.1007/s11154-015-9309-0. View

11.

Rudd C, Taylor A, Schneider H . CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009; 229(1):12-26. PMC: 4186963. DOI: 10.1111/j.1600-065X.2009.00770.x. View

12.

Haanen J, Robert C . Immune Checkpoint Inhibitors. Prog Tumor Res. 2015; 42:55-66. DOI: 10.1159/000437178. View

13.

Kernbauer E, Ding Y, Cadwell K . An enteric virus can replace the beneficial function of commensal bacteria. Nature. 2014; 516(7529):94-8. PMC: 4257755. DOI: 10.1038/nature13960. View

14.

Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis V . Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal. 2012; 5(230):ra46. PMC: 5498435. DOI: 10.1126/scisignal.2002796. View

15.

DArgenio V . Human Microbiome Acquisition and Bioinformatic Challenges in Metagenomic Studies. Int J Mol Sci. 2018; 19(2). PMC: 5855605. DOI: 10.3390/ijms19020383. View

16.

Kamada N, Seo S, Chen G, Nunez G . Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol. 2013; 13(5):321-35. DOI: 10.1038/nri3430. View

17.

Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T . Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol. 2014; 25(10):1935-1940. DOI: 10.1093/annonc/mdu242. View

18.

Buck M, OSullivan D, Pearce E . T cell metabolism drives immunity. J Exp Med. 2015; 212(9):1345-60. PMC: 4548052. DOI: 10.1084/jem.20151159. View

19.

Routy B, Le Chatelier E, Derosa L, Duong C, Alou M, Daillere R . Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2017; 359(6371):91-97. DOI: 10.1126/science.aan3706. View

20.

Kythreotou A, Siddique A, Mauri F, Bower M, Pinato D . PD-L1. J Clin Pathol. 2017; 71(3):189-194. DOI: 10.1136/jclinpath-2017-204853. View